Literature DB >> 9385113

An analytic method for randomized trials with informative censoring: Part II.

J M Robins1.   

Abstract

Consider a randomized trial in which time to the occurrence of a particular disease, say pneumocystic pneumonia in an AIDS trial or breast cancer in a mammographic screening trial, is the failure time of primary interest. Suppose that time to disease is subject to informative censoring by the minimum of time to death, loss to and end of follow-up. In such a trial, the potential censoring time is observed for all study subjects, including failure. In the presence of informative censoring, it is not possible to consistently estimate the effect of treatment on time to disease without imposing additional non-identifiable assumptions. Robins (1995) specified two non-identifiable assumptions that allow one to test for and estimate an effect of treatment on time to disease in the presence of informative censoring. The goal of this paper is to provide a class of consistent and reasonably efficient semiparametric tests and estimators for the treatment effect under these assumptions. The tests in our class, like standard weighted-log-rank tests, are asymptotically distribution-free alpha-level tests under the null hypothesis of no causal effect of treatment on time to disease whenever the censoring and failure distributions are conditionally independent given treatment arm. However, our tests remain asymptotically distribution-free alpha-level tests in the presence of informative censoring provided either of our assumptions are true. In contrast, a weighted log-rank test will be an alpha-level test in the presence of informative censoring only if (1) one of our two non-identifiable assumptions hold, and (2) the distribution of time to censoring is the same in the two treatment arms. We also study the estimation, in the presence of informative censoring, of the effect of treatment on the evolution over time of the mean of repeated measures outcome such as CD4 count.

Entities:  

Mesh:

Year:  1995        PMID: 9385113     DOI: 10.1007/bf00985453

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  2 in total

1.  Estimating exposure effects by modelling the expectation of exposure conditional on confounders.

Authors:  J M Robins; S D Mark; W K Newey
Journal:  Biometrics       Date:  1992-06       Impact factor: 2.571

2.  An analytic method for randomized trials with informative censoring: Part 1.

Authors:  J M Robins
Journal:  Lifetime Data Anal       Date:  1995       Impact factor: 1.588

  2 in total
  5 in total

1.  An analytic method for randomized trials with informative censoring: Part 1.

Authors:  J M Robins
Journal:  Lifetime Data Anal       Date:  1995       Impact factor: 1.588

2.  Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial.

Authors:  Naoki Niikura; Katsuhiko Nakatukasa; Takeshi Amemiya; Ken-Ichi Watanabe; Hironobu Hata; Yuichiro Kikawa; Naoki Taniike; Takashi Yamanaka; Sachiyo Mitsunaga; Kazuhiko Nakagami; Moriyasu Adachi; Naoto Kondo; Yasuyuki Shibuya; Naoki Hayashi; Mariko Naito; Kosuke Kashiwabara; Toshinari Yamashita; Masahiro Umeda; Hirofumi Mukai; Yoshihide Ota
Journal:  Oncologist       Date:  2019-10-08

3.  Semicompeting risks in aging research: methods, issues and needs.

Authors:  Ravi Varadhan; Qian-Li Xue; Karen Bandeen-Roche
Journal:  Lifetime Data Anal       Date:  2014-04-12       Impact factor: 1.588

4.  Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial.

Authors:  Naoki Niikura; Katsuhiko Nakatukasa; Takeshi Amemiya; Ken-Ichi Watanabe; Hironobu Hata; Yuichiro Kikawa; Naoki Taniike; Takashi Yamanaka; Sachiyo Mitsunaga; Kazuhiko Nakagami; Moriyasu Adachi; Naoto Kondo; Yasuyuki Shibuya; Naoki Hayashi; Mariko Naito; Kosuke Kashiwabara; Toshinari Yamashita; Masahiro Umeda; Hirofumi Mukai; Yoshihide Ota
Journal:  Oncologist       Date:  2019-10-08

Review 5.  Survival analysis part IV: further concepts and methods in survival analysis.

Authors:  T G Clark; M J Bradburn; S B Love; D G Altman
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.